"Diphtheria Toxin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ADP-ribosylating polypeptide produced by CORYNEBACTERIUM DIPHTHERIAE that causes the signs and symptoms of DIPHTHERIA. It can be broken into two unequal domains: the smaller, catalytic A domain is the lethal moiety and contains MONO(ADP-RIBOSE) TRANSFERASES which transfers ADP RIBOSE to PEPTIDE ELONGATION FACTOR 2 thereby inhibiting protein synthesis; and the larger B domain that is needed for entry into cells.
| Descriptor ID |
D004167
|
| MeSH Number(s) |
D08.811.913.400.725.115.220 D23.946.123.305
|
| Concept/Terms |
Diphtheria Toxin- Diphtheria Toxin
- Toxin, Corynebacterium Diphtheriae
- Corynebacterium Diphtheriae Toxin
|
Below are MeSH descriptors whose meaning is more general than "Diphtheria Toxin".
Below are MeSH descriptors whose meaning is more specific than "Diphtheria Toxin".
This graph shows the total number of publications written about "Diphtheria Toxin" by people in this website by year, and whether "Diphtheria Toxin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 1 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 2 | 2 | 4 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 3 | 0 | 3 |
| 2007 | 4 | 3 | 7 |
| 2008 | 2 | 3 | 5 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 2 | 3 |
| 2012 | 3 | 2 | 5 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diphtheria Toxin" by people in Profiles.
-
Targeted Apoptosis of Parietal Cells Is Insufficient to Induce Metaplasia in Stomach. Gastroenterology. 2017 03; 152(4):762-766.e7.
-
Resimmune, an anti-CD3e recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 2015 Jun; 100(6):794-800.
-
Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res. 2015 Mar 15; 21(6):1267-72.
-
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and S?zary syndrome. Hematology Am Soc Hematol Educ Program. 2015; 2015:529-44.
-
Can Treg elimination enhance NK cell therapy for AML? Blood. 2014 Jun 19; 123(25):3848-9.
-
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17; 124(3):385-92.
-
Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):377-84.
-
Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302. Biol Blood Marrow Transplant. 2013 Mar; 19(3):481-5.
-
Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and S?zary syndrome. Leuk Lymphoma. 2013 Jan; 54(1):69-75.
-
Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leuk Lymphoma. 2013 Mar; 54(3):514-9.